You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Discontinued Product3-Methoxycarbonylamino-β-carboline (Cat. No. 0550) has been withdrawn from sale for commercial reasons.
Biological Activity for 3-Methoxycarbonylamino-β-carboline
Inverse agonist. Selectively inhibits the sedative action of benzodiazepines without showing convulsant, proconvulsant or anxiogenic activity.
Technical Data for 3-Methoxycarbonylamino-β-carboline
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for 3-Methoxycarbonylamino-β-carboline
References for 3-Methoxycarbonylamino-β-carboline
References are publications that support the biological activity of the product.
Dodd et al (1985) 3-Amino-β-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of D.pam. J.Med.Chem. 28 824 PMID: 2989520
Nutt and Lister (1989) 3-(Methoxycarbonyl)amino-β-carboline reduces both the sedative and anticonvulsant effects of D.pam. Eur.J.Pharmacol. 165 135 PMID: 2767129
View Related Products by Product Action
Keywords: 3-Methoxycarbonylamino-b-carboline, 3-Methoxycarbonylamino-b-carboline supplier, GABAA, Receptors, 0550, Tocris Bioscience
Citations for 3-Methoxycarbonylamino-β-carboline
Citations are publications that use Tocris products.
Currently there are no citations for 3-Methoxycarbonylamino-β-carboline.
Reviews for 3-Methoxycarbonylamino-β-carboline
There are currently no reviews for this product. Be the first to review 3-Methoxycarbonylamino-β-carboline and earn rewards!
Have you used 3-Methoxycarbonylamino-β-carboline?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.